Neratinib

Neratinib is a dual inhibitor of EGFR and HER2 (IC50s = 92 and 59 nM, respectively). It is selective for EGFR and HER2 over a panel of 12 kinases (IC50s = >5,000 nM) but does inhibit VEGFR2 and Src (IC50s = 800 and 1,400 nM, respectively). Neratinib inhibits the proliferation of NCI H508 colorectal cancer cells expressing wild-type or mutant forms of HER2 (IC50s = 0.2-3 nM). It reduces tumor growth in BT474 breast and SKOV3 ovarian cancer mouse xenograft models when administered at a dose of 40 mg/kg. Formulations containing neratinib have been used in the treatment of breast cancer.Formal Name: (2E)-N-[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide. CAS Number: 698387-09-6. Synonyms: HKI-272. Molecular Formula: C30H29ClN6O3. Formula Weight: 557.0. Purity: >98%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 1 mg/ml, DMF:PBS (pH7.2) (1:40): 0.02 mg/ml, DMSO: 2 mg/ml, Ethanol: 1 mg/ml. lambdamax: 260 nm. SMILES: CN(C/C=C/C(NC1=CC(C(NC2=CC(Cl)=C(OCC3=NC=CC=C3)C=C2)=C(C#N)C=N4)=C4C=C1OCC)=O)C. InChi Code: InChI=1S/C30H29ClN6O3/c1-4-39-28-16-25-23(15-26(28)36-29(38)9-7-13-37(2)3)30(20(17-32)18-34-25)35-21-10-11-27(24(31)14-21)40-19-22-8-5-6-12-33-22/h5-12,14-16,18H,4,13,19H2,1-3H3,(H,34,35)(H,36,38)/b9-7+. InChi Key: JWNPDZNEKVCWMY-VQHVLOKHSA-N.